Leuprolide Acetate, a GnRH Agonist, Improves Experimental Autoimmune Encephalomyelitis: A Possible Therapy for Multiple Sclerosis
Gonadotrophin-releasing hormone (GnRH), a well known hypothalamic neuropeptide, has been reported to possess neurotrophic properties. Leuprolide acetate, a synthetic analogue of GnRH is considered to be a very safe and tolerable drug and it has been used for diverse clinical applications, including the treatment of prostate cancer, endometriosis, uterine fibroids, central precocious puberty and in vitro fertilization techniques. The present study was designed to determine whether Leuprolide acetate administration, exerts neurotrophic effects on clinical signs, body weight gain, neurofilaments (NFs) and myelin basic protein (MBP) expression, axonal morphometry and cell infiltration in spinal cord of experimental autoimmune encephalomyelitis (EAE) rats. In this work, we have found that Leuprolide acetate treatment decreases the severity of clinical signs of locomotion, induces a significantly greater body weight gain, increases the MBP and NFs expression, axonal area and cell infiltration in EAE animals. These results suggest the use of this agonist as a potential therapeutic approach for multiple sclerosis.
KeywordsBody weight Neurofilaments Neurotrophic factors Myelin Neuro-regenerative Axon
We would like to express our sincere gratitude to Dr. Kalman Kovacs for reviewing the manuscript and to Dr. Andrés Quintanar-Stephano and Lic. Denisse Calderón Vallejo for the methodological support. We thank to the Consejo Nacional de Ciencia y Tecnología (CONACyT) for scholarship 266788.
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.O’Connor KC, Chitnis T, Griffin DE, Piyasirisilp S, Bar-Or A, Khoury S, Wucherpfennig KW, Hafler DA (2003) Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol 136:140–148PubMedCrossRefGoogle Scholar
- 34.Vickers JC, King AE, Woodhouse A, Kirkcaldie MT, Staal JA, McCormack GH, Blizzard CA, Musgrove RE, Mitew S, Liu Y, Chuckowree JA, Bibari O, Dickson TC (2009) Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system. Brain Res Bull 80:217–223PubMedCrossRefGoogle Scholar
- 35.Avsar T, Korkmaz D, Tütüncü M, Demirci NO, Saip S, Kamasak M, Siva A, Turanli ET (2012) Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis. Mult Scler. doi: 10.1177/1352458511433303 PubMedGoogle Scholar